Fischer Medical Ventures
FISCHER NSE
Fischer Medical Ventures
ChemicalsNSE: FISCHER BSE: 524743 Commodity Chemicals
Key Fundamentals
MicrocapCommodity ChemicalsChemicalsMarket Cap
₹2,230 Cr
Volatility
Moderate
P/E Ratio
94.39
EBITDA
₹43.09 Cr
Return on Equity
0.36%
Debt to Equity
0.28
Book Value
₹6.99
52W High
₹124.7
52W Low
₹31.05
Tapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Strengths
2- Company is expected to give good quarter
- Promoter holding has increased by 0.94% over last quarter.
Weaknesses
3- Stock is trading at 6.10 times its book value
- Company has a low return on equity of 5.54% over last 3 years.
- Company has high debtors of 342 days.
Growth Rate
Revenue Growth
175%
Net Income Growth
—
ROE
-84.14% lower than
3Y
ROCE
-71.21% higher than
3Y
EBITDA Margin (Avg.)
212% higher than
3Y
Quarterly Results
| Particulars | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0 | 20.79 | 10.12 | 39.66 | 11.75 | 49.17 | 23.44 | 86.31 | 101 | 97.54 | 81.92 |
| Expenses | 0 | 18.28 | 10.33 | 39.16 | 11.38 | 46.66 | 19.45 | 70.09 | 79.53 | 101 | 70.67 |
| Operating Profit | 0 | 2.51 | -0.21 | 0.5 | 0.37 | 2.51 | 3.99 | 16.22 | 21.57 | -3.77 | 11.25 |
| OPM % | — | 12.07% | -2.08% | 1.26% | 3.15% | 5.1% | 17.02% | 18.79% | 21.34% | -3.87% | 13.73% |
| Other Income | 0 | 0.47 | 0.69 | 0.05 | 0.38 | 0.15 | 7.47 | 2.48 | 1.09 | 0.77 | 1.48 |
| Interest | 0 | 0.05 | 0.13 | 0.05 | 0.07 | 0.23 | 0.66 | 0.92 | 0.64 | 3.66 | 3.54 |
| Depreciation | 0 | 0.18 | 0.28 | 0.29 | 0.56 | 0.51 | 0.77 | 0.51 | 0.77 | 0.93 | 1.36 |
| PBT | 0 | 2.75 | 0.07 | 0.21 | 0.12 | 1.92 | 10.03 | 17.27 | 21.25 | -7.59 | 7.83 |
| Tax % | — | 6.18% | 271.43% | -38.1% | 350% | 26.04% | 51.55% | 19.46% | 9.18% | 64.03% | 51.6% |
| Net Profit | 0 | 2.59 | -0.12 | 0.29 | -0.29 | 1.31 | 4.86 | 13.9 | 19.23 | -12.44 | 3.79 |
| EPS in Rs | 0 | 0.05 | 0 | 0.01 | -0.01 | 0.02 | 0.07 | 0.21 | 0.3 | -0.19 | 0.06 |
Profit & Loss
| Particulars | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|
| Sales | 0 | 21 | 111 | 309 | 367 |
| Expenses | 0 | 19 | 108 | 266 | 322 |
| Operating Profit | 0 | 2 | 3 | 43 | 45 |
| OPM % | 11% | 9% | 2.6% | 14% | 12% |
| Other Income | 0 | 0 | 1 | 12 | 6 |
| Interest | 0 | 0 | 0 | 6 | 9 |
| Depreciation | 0 | 0 | 2 | 3 | 4 |
| PBT | 0 | 2 | 2 | 46 | 39 |
| Tax % | — | 13% | 45% | 33% | — |
| Net Profit | 0 | 2 | 1 | 31 | 24 |
| EPS in Rs | -0.24 | 0.03 | 0.02 | 0.47 | 0.38 |
| Div. Payout % | 0% | 0% | 22% | 11% | — |
Balance Sheet
| Particulars | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Equity Capital | 0.17 | 54 | 64 | 65 |
| Reserves | 0 | 28 | 274 | 319 |
| Borrowings | 1 | 2 | 85 | 107 |
| Other Liabilities | 0 | 4 | 34 | 180 |
| Total Liabilities | 0 | 86 | 457 | 672 |
| Fixed Assets | 0 | 15 | 24 | 33 |
| CWIP | 0 | 0 | 1 | 3 |
| Investments | 0 | 1 | 11 | 123 |
| Other Assets | 0 | 70 | 421 | 513 |
| Total Assets | 0 | 86 | 457 | 672 |
Cash Flow
| Particulars | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Operating | — | -7 | -87 | -101 |
| Investing | — | -29 | -125 | -5 |
| Financing | — | 37 | 315 | 14 |
| Net Cash Flow | — | 1 | 103 | -92 |
| Free Cash Flow | — | -8 | -93 | -103 |
| CFO/OP | — | -392 | -3,001 | -195 |
Ratios
| Particulars | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Debtor Days | 345 | 398 | 251 | 342 |
| Inventory Days | — | 99 | 36 | 24 |
| Days Payable | — | 48 | 82 | 191 |
| Cash Conversion Cycle | 345 | 449 | 205 | 174 |
| Working Capital Days | 324 | 498 | 40 | 155 |
| ROCE % | — | 5% | 1% | 11% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Fischer Medical Ventures insights
59 extracted metrics + investor summaries across FY10–FY26.
Documents
1
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
9 Apr - Regulation 74(5) certificate filed for quarter ended 31 March 2026. 9 Apr - Regulation 74(5) certificate filed for quarter ended 31 March 2026.
3
Announcement under Regulation 30 (LODR)-Allotment
31 Mar - Promoter converted 6,000,000 warrants into shares at Rs23.40; company received Rs10.53 crore on March 31, 2026. 31 Mar - Promoter converted 6,000,000 warrants into shares at Rs23.40; company received Rs10.53 crore on March 31, 2026.
4
Closure of Trading Window
30 Mar - Trading window closed Apr 01, 2026 until 48 hours after audited FY2025-26 results. 30 Mar - Trading window closed Apr 01, 2026 until 48 hours after audited FY2025-26 results.
5
Board Meeting Outcome for Appointment Of Company Secretary And Compliance Officer
24 Mar - Appointed Balaji Gandla as Company Secretary & Compliance Officer effective 24-Mar-2026; also secretary for wholly-owned subsidiary. 24 Mar - Appointed Balaji Gandla as Company Secretary & Compliance Officer effective 24-Mar-2026; also secretary for wholly-owned subsidiary.
Frequently Asked Questions about Fischer Medical Ventures
What does Fischer Medical Ventures Ltd do?
Fischer Medical Ventures Ltd, earlier known as
Fischer Chemic Ltd, leads a healthcare-technology group. It makes and services medical-imaging equipment and provides
AI-based health screening and digital-health solutions. Its MRI manufacturing plant is located at Andhra Pradesh MedTech Zone (AMT...
Where is Fischer Medical Ventures Ltd (FISCHER) listed?
Fischer Medical Ventures Ltd trades as FISCHER on the NSE and under code 524743 on the BSE.
Which sector does Fischer Medical Ventures Ltd belong to?
Fischer Medical Ventures Ltd is classified under the Chemicals sector, in the Commodity Chemicals industry.
What is the market capitalisation of Fischer Medical Ventures Ltd?
Fischer Medical Ventures Ltd has a market capitalisation of ₹2,230 Cr, which places it in the Small Cap band.
What is the PE ratio of Fischer Medical Ventures Ltd?
Fischer Medical Ventures Ltd trades at a PE ratio of 94.39, against a book value of ₹6.99 per share.
What is the 52-week high and low of Fischer Medical Ventures Ltd?
Over the last 52 weeks Fischer Medical Ventures Ltd has traded between ₹31.05 and ₹124.7.
Does Fischer Medical Ventures Ltd pay dividends?
Fischer Medical Ventures Ltd has a dividend yield of 0.14%.
What is the Return on Equity (ROE) of Fischer Medical Ventures Ltd?
Fischer Medical Ventures Ltd reported a return on equity of 0.36%. Its debt-to-equity ratio is 0.28.
Company Information
Fischer Medical Ventures Ltd, earlier known as Fischer Chemic Ltd, leads a healthcare-technology group. It makes and services medical-imaging equipment and provides AI-based health screening and digital-health solutions. Its MRI manufacturing plant is located at Andhra Pradesh MedTech Zone (AMTZ), Visakhapatnam.[1]
Website fischermv.com
CEO Mr. Ravindran Govindan LLB
Employees 40
Listed 2005-06-08
Face Value ₹ 1
Issued Size 64,85,15,470
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/FISCHER.md for Fischer Medical Ventures Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.